CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
Cena · Sie 19, 2026
Dane fundamentalne na dzień Sie 3, 2026
Zakres 52 tyg.
$29–$85
100% of range
Ocena Analityków
HOLD
21 analysts
Cena Docelowa
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Marża Zysku Netto
-6046.2%
O Crinetics Pharmaceuticals, Inc. - Common Stock Przegląd firmy z Wikipedii
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Czytaj więcej
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
CRNX Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$84.77
Kapitalizacja Rynkowa
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
Przychody (TTM)
$8M
Stopa dywidendy
—
ROE
-43.0%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$29 – $85
CRNX Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-384M
2018-12-31
→
2025-12-31
Marże
-6046.2%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
CRNX
Mediana porównawcza
P/E (TTM)
-17.1
47.9
P/S (TTM)
1052.7
16.2
P/B
8.2
9.3
Price / FCF (Cena / FCF)
-21.1
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
CRNX
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-6714.8%
—
Net Profit Margin (Marża Zysku Netto)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
CRNX
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
12.3
2.7
Quick Ratio (Wskaźnik Szybkości)
12.1
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
CRNX
Mediana porównawcza
Revenue YoY (Przychody R/R)
640.7%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
17.6%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
155.3%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
CRNX
Mediana porównawcza
CRNX Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
TRZYMAJ
21 analityków
- Mocne kupno 3 14,3%
- Kup 4 19,0%
- Trzymaj 14 66,7%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
10 analityków · 2026-08-13
Mediana
$85.00
Średnia
$85.50
← Poniżej wszystkich celów
$84.77
Niski
$85.00
Wysoki
$90.00
Średni cel
$85.00
+0,3%
Średnia cel
$85.50
+0,9%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-0.01%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-1.14 | $-1.23 | 0.09% |
| 31 marca 2026 | $-1.23 | $-1.26 | 0.03% |
| 31 grudnia 2025 | $-1.29 | $-1.39 | 0.10% |
| 30 września 2025 | $-1.38 | $-1.28 | -0.10% |
| 30 czerwca 2025 | $-1.23 | $-1.12 | -0.11% |
| 31 marca 2025 | $-1.04 | $-0.96 | -0.08% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Bilans 24
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Przepływy pieniężne 13
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Płynność i wypłacalność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Rachunek zysków i strat 15
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Bilans 23
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Przepływy pieniężne 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Rentowność 6
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $8M | $1M | $4M | $5M | $1M |
| Marża Operacyjna % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Zysk netto | $-465M | $-298M | $-215M | $-164M | $-108M |
| Rozwodniony EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Wskaźnik Szybkości | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-384M | $-230M | $-171M | $-117M | $-89M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 287 emitentów · $3.2B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 63 (+11 vs poprzedni kw.) | 30 (-13 vs poprzedni kw.) | 95 (-17 vs poprzedni kw.) | 63 (+3 vs poprzedni kw.) | +11.4M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $486 250 673 | 12 994 406 | 15,13% | Akcje |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336 372 047 | 8 989 098 | 10,46% | Akcje |
| Driehaus Capital Management LLC | $241 866 078 | 6 463 551 | 7,52% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $237 002 526 | 6 333 579 | 7,37% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180 836 416 | 4 832 614 | 5,63% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $177 567 704 | 4 745 262 | 5,52% | Akcje |
| STATE STREET CORP | $100 635 477 | 2 689 350 | 3,13% | Akcje |
| Bellevue Group AG | $98 040 400 | 2 620 000 | 3,05% | Akcje |
| BAKER BROS. ADVISORS LP | $87 991 820 | 2 351 465 | 2,74% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $87 542 675 | 2 338 905 | 2,72% | Akcje |
| Polar Capital Holdings Plc | $85 108 460 | 2 274 411 | 2,65% | Akcje |
| Pictet Asset Management Holding SA | $77 572 984 | 2 075 375 | 2,41% | Akcje |
| Siren, L.L.C. | $53 165 887 | 1 420 788 | 1,65% | Akcje |
| First Light Asset Management, LLC | $50 923 606 | 1 360 866 | 1,58% | Akcje |
| NOVO HOLDINGS A/S | $49 394 400 | 1 320 000 | 1,54% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $47 245 129 | 1 262 562 | 1,47% | Akcje |
| ADAR1 Capital Management, LLC | $45 730 234 | 1 222 080 | 1,42% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $44 555 208 | 1 190 679 | 1,39% | Akcje |
| MONTANOVA CAPITAL, LLC | $44 390 560 | 1 186 279 | 1,38% | Akcje |
| ORBIMED ADVISORS LLC | $37 382 580 | 999 000 | 1,16% | Akcje |
| Hood River Capital Management LLC | $36 259 830 | 968 996 | 1,13% | Akcje |
| GOLDMAN SACHS GROUP INC | $34 657 132 | 926 166 | 1,08% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32 841 401 | 877 643 | 1,02% | Akcje |
| Aberdeen Group plc | $30 699 181 | 820 395 | 0,95% | Akcje |
| Candriam S.C.A. | $30 618 690 | 819 032 | 0,95% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $28 230 995 | 754 436 | 0,88% | Akcje |
| Fisher Asset Management, LLC | $27 748 912 | 741 553 | 0,86% | Akcje |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17 709 036 | 479 400 | 0,55% | Akcje |
| AMERIPRISE FINANCIAL INC | $17 451 149 | 466 356 | 0,54% | Akcje |
| Impax Asset Management Group plc | $16 277 700 | 435 000 | 0,51% | Akcje |
| Prosight Management, LP | $14 020 002 | 374 666 | 0,44% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13 991 714 | 373 910 | 0,44% | Akcje |
| KENNEDY CAPITAL MANAGEMENT LLC | $13 685 018 | 365 714 | 0,43% | Akcje |
| BRAUN STACEY ASSOCIATES INC | $13 027 511 | 348 143 | 0,41% | Akcje |
| Fiera Capital Corp | $12 395 263 | 331 247 | 0,39% | Akcje |
| BANK OF AMERICA CORP /DE/ | $11 271 877 | 301 226 | 0,35% | Akcje |
| Defilade Capital Management, L.P. | $8 959 845 | 239 440 | 0,28% | Akcje |
| SEB Asset Management AB | $8 003 786 | 213 891 | 0,25% | Akcje |
| Foresite Capital Management VI LLC | $7 933 414 | 212 010 | 0,25% | Akcje |
| RICE HALL JAMES & ASSOCIATES, LLC | $7 346 220 | 196 318 | 0,23% | Akcje |
| TD Asset Management Inc | $7 152 534 | 191 142 | 0,22% | Akcje |
| Swiss National Bank | $6 877 796 | 183 800 | 0,21% | Akcje |
| SEGALL BRYANT & HAMILL, LLC | $6 855 307 | 183 199 | 0,21% | Akcje |
| BlackRock, Inc. | $6 781 290 | 181 221 | 0,21% | Akcje |
| JENNISON ASSOCIATES LLC | $6 056 839 | 161 861 | 0,19% | Akcje |
| New Leaf Venture Partners, L.L.C. | $5 872 650 | 141 000 | 0,18% | Akcje |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5 865 136 | 156 738 | 0,18% | Akcje |
| Foresite Capital Management IV, LLC | $5 613 000 | 150 000 | 0,17% | Akcje |
| Bank of New York Mellon Corp | $5 581 754 | 149 165 | 0,17% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $5 508 898 | 147 218 | 0,17% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $5 471 384 | 146 216 | 0,17% | Akcje |
| Moody Aldrich Partners LLC | $5 466 201 | 146 077 | 0,17% | Akcje |
| Ishara Investments LP | $5 369 770 | 143 500 | 0,17% | Akcje |
| CITADEL ADVISORS LLC | $5 176 271 | 138 329 | 0,16% | Akcje |
| RHUMBLINE ADVISERS | $4 861 141 | 129 908 | 0,15% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $4 782 618 | 131 680 | 0,15% | Akcje |
| GordonMD Global Investments LP | $4 751 779 | 126 985 | 0,15% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4 712 974 | 125 948 | 0,15% | Akcje |
| JANUS HENDERSON GROUP PLC | $4 700 428 | 129 392 | 0,15% | Akcje |
| Cormorant Asset Management, LP | $4 677 500 | 125 000 | 0,15% | Akcje |
| SECTOR GAMMA AS | $4 289 380 | 114 628 | 0,13% | Akcje |
| XTX Topco Ltd | $4 164 547 | 111 292 | 0,13% | Akcje |
| ALPS ADVISORS INC | $3 981 825 | 106 409 | 0,12% | Akcje |
| FEDERATED HERMES, INC. | $3 957 390 | 105 756 | 0,12% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3 834 048 | 105 563 | 0,12% | Akcje |
| Nuveen Asset Management, LLC | $3 760 151 | 73 541 | 0,12% | Akcje |
| Burkehill Global Management, LP | $3 742 000 | 100 000 | 0,12% | Akcje |
| Nuveen, LLC | $3 619 262 | 96 720 | 0,11% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $3 484 251 | 93 112 | 0,11% | Akcje |
| MORGAN STANLEY | $3 320 829 | 88 744 | 0,10% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $3 266 729 | 87 299 | 0,10% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $3 254 754 | 86 979 | 0,10% | Akcje |
| AWM Investment Company, Inc. | $3 180 700 | 85 000 | 0,10% | Akcje |
| Odyssean, LLC | $3 160 344 | 84 456 | 0,10% | Akcje |
| Affinity Asset Advisors, LLC | $2 806 500 | 75 000 | 0,09% | Akcje |
| ALGERT GLOBAL LLC | $2 714 147 | 72 532 | 0,08% | Akcje |
| ExodusPoint Capital Management, LP | $2 652 404 | 70 882 | 0,08% | Akcje |
| Ensign Peak Advisors, Inc | $2 507 290 | 67 004 | 0,08% | Akcje |
| BARCLAYS PLC | $2 466 127 | 65 904 | 0,08% | Akcje |
| FIRST TRUST ADVISORS LP | $2 370 631 | 63 352 | 0,07% | Akcje |
| Man Group plc | $2 284 229 | 61 043 | 0,07% | Akcje |
| MetLife Investment Management, LLC | $2 258 709 | 60 361 | 0,07% | Akcje |
| CITIGROUP INC | $2 255 229 | 60 268 | 0,07% | Akcje |
| Longaeva Partners L.P. | $2 184 879 | 58 388 | 0,07% | Akcje |
| Swedbank AB | $2 155 392 | 57 600 | 0,07% | Akcje |
| STATE OF WISCONSIN INVESTMENT BOARD | $2 068 016 | 55 265 | 0,06% | Akcje |
| Jump Financial, LLC | $1 923 388 | 51 400 | 0,06% | Akcje |
| Lighthouse Investment Partners, LLC | $1 871 000 | 50 000 | 0,06% | Akcje |
| Vestmark Advisory Solutions, Inc. | $1 823 252 | 48 724 | 0,06% | Akcje |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1 787 254 | 47 762 | 0,06% | Akcje |
| VANGUARD GROUP INC | $1 774 626 | 38 123 | 0,06% | Akcje |
| Point72 Asset Management, L.P. | $1 735 577 | 46 381 | 0,05% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $1 696 398 | 45 334 | 0,05% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $1 606 254 | 42 925 | 0,05% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 549 188 | 41 400 | 0,05% | Opcja kupna |
| Invesco Ltd. | $1 545 446 | 41 300 | 0,05% | Akcje |
| Vanguard Global Advisers, LLC | $1 485 986 | 39 711 | 0,05% | Akcje |
| HighMark Wealth Management LLC | $1 444 224 | 38 595 | 0,04% | Akcje |
| OAK RIDGE INVESTMENTS LLC | $1 405 046 | 37 548 | 0,04% | Akcje |
| Orion Porfolio Solutions, LLC | $1 404 234 | 37 526 | 0,04% | Akcje |
Insiderzy spółki 20 insiderów · 9 dyrektorzy generalni · 10 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10 marca 2025 A | 52 000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26 września 2024 M | 111 092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19 marca 2025 S | 87 491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12 czerwca 2025 M | 99 713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19 marca 2025 S | 72 233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10 stycznia 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 5 lipca 2024 M | 29 259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17 października 2023 M | 43 210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28 lutego 2022 A | 176 995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Dyrektor | 2 lipca 2026 S | 19 225 | 0 | 1 | $-120 000 |
| Caren Deardorf | Dyrektor | 18 czerwca 2026 A | 22 225 | 0 | 0 | $0 |
| Weston Nichols | Dyrektor | 18 czerwca 2026 A | 22 225 | 0 | 0 | $0 |
| Stephanie Okey | Dyrektor | 18 czerwca 2026 A | 12 325 | 0 | 2 | $-246 143 |
| Matthew K Fust | Dyrektor | 18 czerwca 2026 A | 28 761 | 0 | 0 | $0 |
| Camille L Bedrosian | Dyrektor | 18 czerwca 2026 A | 22 225 | 0 | 0 | $0 |
| Wendell Wierenga | Dyrektor | 18 czerwca 2026 A | 122 071 | 0 | 0 | $0 |
| Wendall Wierenga | Dyrektor | 11 czerwca 2025 A | 116 146 | 0 | 0 | $0 |
| Stephen W Kaldor | Dyrektor | 19 czerwca 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Dyrektor | 21 czerwca 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 7 sierpnia 2026 M | 424 706 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 1 akcja
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 zgłoszenia | 1 marca 2024 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 55 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107 892 NS | 31 maja 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 1,65% | 19 000 NS | 31 maja 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4 666 NS | 30 kwietnia 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18 743 NS | 30 kwietnia 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11 043 NS | 31 maja 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,28% | 93 045 NS | 30 kwietnia 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38 553 NS | 30 kwietnia 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3 872 NS | 31 maja 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3 142 NS | 30 kwietnia 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18 879 NS | 30 kwietnia 2026 | N-PORT |
| RSSL · Global X Funds | 0,12% | 42 391 NS | 30 kwietnia 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31 759 NS | 30 kwietnia 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4 601 NS | 31 maja 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492 431 NS | 31 maja 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24 991 NS | 30 kwietnia 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41 183 NS | 30 kwietnia 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196 549 NS | 30 kwietnia 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3 599 NS | 31 maja 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5 196 NS | 30 kwietnia 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31 maja 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3 643 NS | 31 maja 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5 689 NS | 31 maja 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3 773 NS | 31 maja 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31 maja 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 125 853 NS | 30 kwietnia 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28 694 NS | 31 maja 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5 863 NS | 30 kwietnia 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3 388 NS | 30 kwietnia 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,01% | 31 413 NS | 30 kwietnia 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,01% | 15 024 NS | 30 kwietnia 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,01% | 60 503 NS | 31 maja 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,00% | 468 NS | 30 kwietnia 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VBK · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 lipca 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 lipca 2026 | Dziennie |
| ITOT · iShares Trust | — | — | 5 sierpnia 2026 | Dziennie |
| IWV · iShares Trust | — | — | 18 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | — | — | 18 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | — | — | 18 sierpnia 2026 | Dziennie |
| IBB · iShares Trust | — | — | 18 sierpnia 2026 | Dziennie |
| IHE · iShares Trust | — | — | 18 sierpnia 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 4 sierpnia 2026 | Dziennie |
| OMFS · Invesco Exchange-Traded Self-Indexe… | — | — | 13 lipca 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | — | — | 20 lipca 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | — | — | 30 lipca 2026 | Dziennie |